Gabriela Meresman

Dr. Gabriela Meresman

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2000 in Fertility and Sterility
Verified
Journal Article
Closed access
GMGabriela Meresman
Gabriela Meresman
SVSusana Vighi
Susana Vighi
RBRicardo A Buquet
Ricardo A Buquet
OCOscar Contreras-Ortiz
Oscar Contreras-Ortiz
MTMarta Tesone
Marta Tesone
LRLı́a S Rumi
Lı́a S Rumi

1 June 2002 in Fertility and Sterility
Verified
Journal Article
Closed access
GMGabriela Meresman
Gabriela Meresman
LALuis Augé
Luis Augé
RBRosa I. Barañao
Rosa I. Barañao
ELEduardo Lombardi
Eduardo Lombardi
MTMarta Tesone
Marta Tesone
CSCarlos Sueldo
Carlos Sueldo

18 October 2012 in Human Reproduction
Verified
Journal Article
Open access
PDF file
ARA.G. Ricci
A.G. Ricci
COC.N. Olivares
C.N. Olivares
MBM.A. Bilotas
M.A. Bilotas
JBJ.I. Bastón
J.I. Bastón
JSJ.J. Singla
J.J. Singla
RBR.I. Barañao
R.I. Barañao
Can resveratrol and epigallocatechin-3-gallate (EGCG) inhibit the growth and survival of endometriotic-like lesions in vivo in a BALB/c model of endometriosis, and in vitro in primary cultures of human endometrial epithelial cells (EECs)? Resveratrol and EGCG exerted a potent inhibitory effect on the development of endometriosis in a BALB/c murine model and on the survival of EECs. Endometriosis is a common condition associated with infertility and pelvic pain in women of reproductive age. Resveratrol and EGCG are two polyphenols with anticarcinogenic and antioxidant properties that have been proposed as natural therapies to treat endometriosis. Fifty-six 2-month-old female BALB/c mice underwent surgical induction of endometriosis. Treatments with resveratrol or EGCG started 15 days post-surgery and continued for 4 weeks. Human biopsies were taken with a metal Novak curette from the posterior uterine wall from 16 patients with untreated endometriosis and 15 controls who underwent diagnostic laparoscopy for infertility. After the treatments, animals were sacrificed and lesions were counted, measured, excised and fixed. Immunohistochemistry for proliferating cell nuclear antigen and CD34 was performed for cell proliferation and vascularization assessment in the lesions. The terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) technique was performed for apoptosis evaluation. Peritoneal fluid was collected to analyze vascular endothelial growth factor levels. Human EECs were purified from proliferative-phase endometrial biopsies and cultured. The effect of both polyphenols on cell proliferation was determined by a colorimetric assay using the CellTiter 96®AQueous One Solution Cell Proliferation Assay kit and on apoptosis by the TUNEL technique, using an In Situ Cell Death Detection Kit with Fluorescein. In the mouse model, both treatments significantly reduced the mean number (P < 0.05 versus control) and the volume of established lesions (P < 0.05 versus control). Treatments consistently statistically significantly diminished cell proliferation (resveratrol P < 0.01 and EGCG P < 0.05, versus control), reduced vascular density (resveratrol P < 0.01 and EGCG P < 0.001, versus control) and increased apoptosis within the lesions (resveratrol P < 0.01 and EGCG P < 0.05, versus control). Both compounds induced reduction in human EEC proliferation (P < 0.05 versus basal) and increased apoptosis (P < 0.05 versus basal) in primary cultures. In vitro studies were only carried out in epithelial cells from human eutopic endometrium. The present findings are promising and will assist the development of novel natural treatments for endometriosis. This study was supported by ANPCYT (PICT 6384 BID 1201 OC-AR) and CONICET (PIP 5471), Argentina. None of the authors has any conflict of interest to declare.

1 July 2011 in Reproductive Sciences
Verified
Journal Article
Open access
PDF file
ARAnalía Gabriela Ricci
Analía Gabriela Ricci
COCarla Noemí Olivares
Carla Noemí Olivares
MBMariela Andrea Bilotas
Mariela Andrea Bilotas
GMGabriela Meresman
Gabriela Meresman
RBRosa Inés Barañao
Rosa Inés Barañao
The main factor involved in neovascularization of ectopic endometrial tissue in endometriosis is the vascular endothelial growth factor (VEGF), which is produced both by the endometrial implant and by peritoneal macrophages. On the other hand, bevacizumab is an antiangiogenic agent used in the treatment of different tumors, like colorectal, pulmonary, and recently mammary. We evaluated the effect of the inhibition of VEGF activity with bevacizumab (Avastin) on ectopic endometrial growth in a murine model of endometriosis. Two months old female BALB/c mice had surgery performed to induce endometriotic-like lesions. Treatment with bevacizumab started on post-surgery day 15 and continued during 2 weeks. Then, animals were sacrificed, peritoneal fluid was collected, and endometriotic-like lesions were counted, measured, and removed. Cell proliferation, vascular density, and apoptosis were assessed by immunohistochemistry for proliferating cell nuclear antigen (PCNA), immunohistochemistry for CD34, and Terminal Deoxynucleotidil Transferase-Mediated dUTP Nick End Labeling (TUNEL), respectively. Vascular endothelial growth factor levels were evaluated in the peritoneal fluid by enzyme-linked immunoassay (ELISA). Treatment with bevacizumab significantly inhibited endometriotic lesion development (P < .05). Consistently, bevacizumab significantly inhibited cell proliferation in lesions (P < .01), reduced vascular density (P < .001), as well as increased the apoptotic cell percentage (P < .001). In addition, bevacizumab reduced VEGF levels in peritoneal fluid of endometriosis-induced animals (P < .05). In conclusion, this study suggests a direct effect of bevacizumab on the reduction of endometrial implant growth and supports further research on VEGF inhibition as a novel therapeutic modality in endometriosis.

1 September 2003 in Human Reproduction
Verified
Journal Article
Open access
PDF file
GMGabriela Meresman
Gabriela Meresman
MBMariela A. Bilotas
Mariela A. Bilotas
ELEduardo Lombardi
Eduardo Lombardi
MTMarta Tesone
Marta Tesone
CSCarlos Sueldo
Carlos Sueldo
RBRosa I. Barañao
Rosa I. Barañao
BACKGROUND: The aim of the present study was to evaluate the effect of GnRH analogues on the in‐vitro eutopic endometrial cell apoptosis and release of interleukin‐1β (IL‐1β) and vascular endothelial growth factor (VEGF). METHODS: Biopsy specimens of eutopic endometrium obtained from 16 women with untreated endometriosis and 14 controls were studied. Apoptosis, IL‐1β and VEGF release were evaluated in epithelial endometrial cell cultures after incubation with leuprolide acetate (LA) as GnRH agonist, antide as GnRH antagonist, and a combination of both. The percentage of apoptotic cells was evaluated by the acridine orange–ethidium bromide technique, and IL‐1β and VEGF concentrations were assessed by using commercial enzyme‐linked immunosorbent assay (ELISA) kits. RESULTS: We found that LA (100 ng/ml) enhanced apoptosis in endometrial cell cultures from endometriosis patients and controls and this effect was reversed by antide at 10–7 mol/l. IL‐1β and VEGF release was downregulated by LA in cultures from controls and endometriosis patients. The addition of antide 10–7 mol/l reversed this inhibition. Endometrial cultures treated with antide at 10–7 mol/l did not show any significant effects compared with basal conditions. CONCLUSIONS: GnRH agonists appear to have a direct effect in endometrial cells cultures, by enhancing the percentage of apoptotic cells and decreasing the release of pro‐mitogenic cytokines such as IL‐1β and VEGF.

22 October 2019 in Gynecological Endocrinology
Verified
Journal Article
Closed access
DMDaniela Madanes
Daniela Madanes
MBMariela A. Bilotas
Mariela A. Bilotas
JBJuan I. Bastón
Juan I. Bastón
JSJosé J. Singla
José J. Singla
GMGabriela Meresman
Gabriela Meresman
ARAnalía G. Ricci
Analía G. Ricci
Based on the inflammatory nature and hormone-dependency of endometriosis, PI3K/AKT signaling appears to influence its progression. Could the endometriosis stages be linked to differential changes in PI3K/AKT pathway regulation? The objective is to evaluate the expression of PI3K, PTEN, AKT and p-AKT in endometrial human biopsies, according to the presence or absence of the disease, and to assess the underlying differences regarding the endometriosis stages. Biopsy specimens of the ectopic and eutopic endometrium were obtained from twenty women with untreated peritoneal endometriosis as well as endometrium biopsies from nine controls. Our study revealed an increased expression of PI3K in eutopic and ectopic endometrium from patients with endometriosis, and a reduced expression of PTEN and increased levels of AKT phosphorylation, compared to control endometrium. Both eutopic and ectopic endometrium from patients with minimal-mild endometriosis expressed a significant reduced PTEN level compared to the respective endometrium from patients with moderate-severe endometriosis. The ratio p-AKT/total AKT showed higher levels of AKT phosphorylation in endometriotic tissue from patients with minimal-mild endometriosis. This study has firmly confirmed the alteration in PI3K/AKT pathway regulation and demonstrated clear differences between the stages of endometriosis, emphasizing the importance of this pathway in the first stage of the disease.